CST, 44621SF, MLKL (E7V4W) Mouse Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying MLKL. Validated for Western Blotting,Immunofluorescence (Immunocytochemistry),ELISA+. Highly specific and rigorously validated in-house, MLKL (E7V4W) Mouse Monoclonal Antibody (BSA and Azide Free) (CST #44621) is ready to ship. Product Usage Information This product is the carrier free version of product #26539. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 26539 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity MLKL (E7V4W) Mouse Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total MLKL protein. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human MLKL protein. Background Necroptosis, a regulated pathway for necrotic cell death, is triggered by a number of inflammatory signals including cytokines in the tumor necrosis factor (TNF) family, pathogen sensors such as toll-like receptors (TLRs), and ischemic injury (1,2). The process is negatively regulated by caspases and is initiated through a complex containing the RIP1 and RIP3 kinases, typically referred to as the necrosome. Mixed lineage kinase domain-like protein (MLKL) is a pseudokinase that was identified as a downstream target of RIP3 in the necroptosis pathway (3,4). During necroptosis RIP3 is phosphorylated at Ser227, which recruits MLKL and leads to its phosphorylation at Thr357 and Ser358 (3). Knockdown of MLKL through multiple mechanisms results in inhibition of necroptosis (3-5). While the precise mechanism for MLKL-induced necroptosis is unclear, some studies have shown that necroptosis leads to oligomerization of MLKL and translocation to the plasma membrane, where it affects membrane integrity (6-9). Alternate Names FLJ34389; hMLKL; mixed lineage kinase domain like pseudokinase; mixed lineage kinase domain-like; Mixed lineage kinase domain-like protein; MLKL Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 54 Source/Isotype: Mouse IgG2b kappa